Medical data platform company JNPMEDI (CEO Kwunho Jeong) announced on the 2nd that it is embarking on an aggressive recruitment drive to significantly expand its workforce.
JNPMEDI plans to recruit a large number of new and experienced developers for its Development Division (CXD) through large-scale hiring in the second half of the year, aiming to enhance and expand its solution, Maven Clinical Cloud. The hiring fields include △Frontend, △Backend, △Full-stack, △Product Owner, △Product Designer, and △Product QA Engineer, totaling six positions. Detailed job qualifications can be found on the official JNPMEDI recruitment website.
JNPMEDI independently develops and operates the clinical trial solution 'Maven Clinical Cloud' based on its unique technologies such as blockchain and cloud computing. Maven Clinical Cloud is a SaaS-based one-stop solution that allows selective adoption of necessary functions according to the scale and purpose of the clinical trial. It boasts high convenience through the implementation of a microservices architecture, ensuring smooth operation and maintenance.
The JNPMEDI development team comprises talents with solid experience from global IT companies. To attract top talent, JNPMEDI has its headquarters in Incheon Songdo, the top bio-cluster in Korea, and has recently shown remarkable growth by doubling its office space along with large-scale recruitment.
JNPMEDI is also noted for continuously improving the work environment and welfare benefits to enhance employee focus and offers talent development programs benchmarked against global companies. It provides △the best performance equipment and software, △top-level welfare points in the startup industry, △meals (breakfast, lunch, and dinner), △support for real estate brokerage fees and relocation settlement, △education fees, and △book purchase costs, offering a wide range of benefits for individual growth and development. Additionally, JNPMEDI has established a close collaboration system to prevent communication gaps between departments through onboarding programs that help new employees quickly adapt, town hall meetings to share business status and plans, and open forums for constructive feedback.
The hiring process includes document screening, coding test, practical interview, executive interview, and CEO interview. Applicants can submit their resumes in a free format through the official JNPMEDI recruitment website.
JNPMEDI's CTO, Youngyong Park, said, "As a company leading the advancement of the clinical market, JNPMEDI is recruiting talent to drive digital innovation in the clinical trial industry," adding, "We look forward to having excellent talents who possess curiosity, perseverance, passion, and a challenging spirit join us."
Meanwhile, despite the downturn in the startup investment market last November, JNPMEDI completed a Series A funding round of KRW 14 billion, securing a total of KRW 16 billion in cumulative investment. Pavilion Capital, a growth investment subsidiary of Singapore's largest sovereign wealth fund Temasek, led the investment, and all existing seed investors, including Kakao Ventures, Murex Partners, Ajou IB Investment, and Gentium Partners, participated in the reinvestment, recognizing JNPMEDI's high growth potential.
Medical data platform company JNPMEDI (CEO Kwunho Jeong) announced on the 2nd that it is embarking on an aggressive recruitment drive to significantly expand its workforce.
JNPMEDI plans to recruit a large number of new and experienced developers for its Development Division (CXD) through large-scale hiring in the second half of the year, aiming to enhance and expand its solution, Maven Clinical Cloud. The hiring fields include △Frontend, △Backend, △Full-stack, △Product Owner, △Product Designer, and △Product QA Engineer, totaling six positions. Detailed job qualifications can be found on the official JNPMEDI recruitment website.
JNPMEDI independently develops and operates the clinical trial solution 'Maven Clinical Cloud' based on its unique technologies such as blockchain and cloud computing. Maven Clinical Cloud is a SaaS-based one-stop solution that allows selective adoption of necessary functions according to the scale and purpose of the clinical trial. It boasts high convenience through the implementation of a microservices architecture, ensuring smooth operation and maintenance.
The JNPMEDI development team comprises talents with solid experience from global IT companies. To attract top talent, JNPMEDI has its headquarters in Incheon Songdo, the top bio-cluster in Korea, and has recently shown remarkable growth by doubling its office space along with large-scale recruitment.
JNPMEDI is also noted for continuously improving the work environment and welfare benefits to enhance employee focus and offers talent development programs benchmarked against global companies. It provides △the best performance equipment and software, △top-level welfare points in the startup industry, △meals (breakfast, lunch, and dinner), △support for real estate brokerage fees and relocation settlement, △education fees, and △book purchase costs, offering a wide range of benefits for individual growth and development. Additionally, JNPMEDI has established a close collaboration system to prevent communication gaps between departments through onboarding programs that help new employees quickly adapt, town hall meetings to share business status and plans, and open forums for constructive feedback.
The hiring process includes document screening, coding test, practical interview, executive interview, and CEO interview. Applicants can submit their resumes in a free format through the official JNPMEDI recruitment website.
JNPMEDI's CTO, Youngyong Park, said, "As a company leading the advancement of the clinical market, JNPMEDI is recruiting talent to drive digital innovation in the clinical trial industry," adding, "We look forward to having excellent talents who possess curiosity, perseverance, passion, and a challenging spirit join us."
Meanwhile, despite the downturn in the startup investment market last November, JNPMEDI completed a Series A funding round of KRW 14 billion, securing a total of KRW 16 billion in cumulative investment. Pavilion Capital, a growth investment subsidiary of Singapore's largest sovereign wealth fund Temasek, led the investment, and all existing seed investors, including Kakao Ventures, Murex Partners, Ajou IB Investment, and Gentium Partners, participated in the reinvestment, recognizing JNPMEDI's high growth potential.